BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by ...

Credit: Getty Images. A PDUFA target date of May 29, 2023 has been set for the application. The Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee unanimously voted 12-0 in ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking IL-13 ...

Credit: Innoviva. Xacduro is available as a kit containing a single dose vial of sulbactam 1g and 2 single-dose vials of durlobactam (0.5g in each vial). Xacduro ® (sulbactam for injection; ...

A research team has discovered a fundamental mechanism that helps the dreaded hospital pathogen Acinetobacter baumannii to survive. This mechanism explains why the pathogen is difficult to eradicate ...

ESCMID is the premier annual congress of the European Society of Clinical Microbiology and Infectious Diseases. It takes place from April 17 - 21, 2026 in Munich, Germany.

New research has shown that a lack of dietary zinc can boost the chances of a lung infection caused by Acinetobacter baumannii bacteria; these pathogens are a major reason why people on ventilators ...

SHANGHAI and SAN FRANCISCO, May 18, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), an innovative commercial stage biopharmaceutical company, today announced dosing of the first Chinese ...

In an effort to illustrate that genomic surveillance can build the foundation for scaleable precision phage therapy, an international collaboration analyzed the genomes of over 15,000 cases of ...